Japan's Ministry Of Health, Labour And Welfare Has Accepted For Review GSK's New Drug Application For Blenrep (Belantamab Mafodotin) In Combination With Bortezomib Plus Dexamethasone Or Pomalidomide Plus Dexamethasone For Relapsed Or Refractory...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.